1stOncology™: Cancer Intelligence Service – Page 13197 – 1stOncology is recognized as a Top 10 Global Pharma Analytic Provider

October 2019 Investor Presentation

On October 4, 2019 Advaxis presented the corporate presentation (Presentation, Advaxis, OCT 4, 2019, View Source [SID1234552244]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

Schedule Your 30 min Free Demo!

Quest Diagnostics To Release Third Quarter 2019 Financial Results On October 22

On October 4, 2019 Quest Diagnostics Incorporated (NYSE: DGX), the world’s leading provider of diagnostic information services, reported that it will report third quarter 2019 results on Tuesday, October 22, 2019, before the market opens (Press release, Quest Diagnostics, OCT 4, 2019, View Source [SID1234540061]). It will hold its quarterly conference call to discuss the results beginning at 8:30 a.m. Eastern Time on that day.

The conference call can be accessed by dialing 888-455-0391 within the U.S. and Canada, or 773-756-0467 internationally, using the passcode: "Investor." The earnings release and live webcast will be posted on www.QuestDiagnostics.com/investor. The company suggests participants dial in approximately 10 minutes before the call.

A replay of the call may be accessed online at www.QuestDiagnostics.com/investor or by phone at
888-566-0408 for domestic callers or 402-998-0597 for international callers; no passcode is required. Telephone replays will be available from approximately 10:30 a.m. Eastern Time on October 22, 2019 until midnight Eastern Time on November 5, 2019.

Anyone listening to the call is encouraged to read the company’s periodic reports on file with the Securities and Exchange Commission, including the discussion of risk factors and historical results of operations and financial condition in those reports.

Quest Diagnostics To Release Third Quarter 2019 Financial Results On October 22

On October 4, 2019 Quest Diagnostics Incorporated (NYSE: DGX), the world’s leading provider of diagnostic information services, reported that it will report third quarter 2019 results on Tuesday, October 22, 2019, before the market opens (Press release, Quest Diagnostics, OCT 4, 2019, View Source [SID1234540060]). It will hold its quarterly conference call to discuss the results beginning at 8:30 a.m. Eastern Time on that day.

BioCentury: Elicio to Advance Pancreatic, HPV Vaccines, CAR T Booster With $33M B Round

On October 4, 2019 Elicio Therapeutics reported that Six months after raising a $30 million series A round, Elicio has added $33 million via its B round to begin Phase I/II testing of its KRAS-driven cancer vaccine ELI-002 and advance its other immunotherapies (Press release, Elicio Therapeutics, OCT 4, 2019, View Source [SID1234540058]).

Elicio Therapeutics’ Amphiphile platform, which attaches antigens to an albumin-binding lipid tail for transport to lymph nodes, was developed by co-founder Darrell Irvine. Irvine is a Massachusetts Institute of Technology professor of materials science and engineering and of biological engineering.

CEO Robert Connelly told BioCentury that the series B, led by new investor Livzon Pharmaceutical Group, was driven by Elicio’s preclinical data, investor interest in KRAS and the potential for a near-term clinical readout for ELI-002.

In August, Elicio presented preclinical data at the Immuno-Oncology Summit in Boston showing that ELI-002 generated immune responses against all common KRAS mutations, resulting in cytolytic activity against cells expressing the mutations. It plans to begin a controlled Phase I/II trial in 90 post-resection pancreatic cancer patients next half, with initial data due in 2H20.

The vaccine contains seven Amphiphile-modified peptides, each corresponding to the seven KRAS mutations driving the majority of KRAS-driven cancers. Connelly said that the most commonly targeted KRAS mutation, G12C, isn’t a major driver of pancreatic cancer. By immunizing against the seven KRAS mutations, ELI-002 could target the cancer’s existing mutation as well as prepare the immune system to respond to emergence of a new KRAS mutation.

ELI-002’s next indications are colorectal cancer, which Connelly said is proving to not be a G12C-driven cancer, and non-small cell lung cancer. See View Source for full story

Aeterna Zentaris Announces Appointment of New President and Chief Executive Officer

On October 4, 2019 Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) reported the appointment of Klaus Paulini as President and Chief Executive Officer of the Company, replacing Michael Ward. Dr. Paulini will also serve as a Director of the Company (Press release, AEterna Zentaris, OCT 4, 2019, View Source [SID1234540057]).

Dr. Paulini will continue to be based in Frankfurt, Germany, and his appointment as President and Chief Executive Officer aligns with the Company’s refocus on its operations in Germany. The Company’s registered office will remain in Toronto, Ontario, Canada.

Dr. Paulini began his career in the pharmaceutical industry at ASTA Medica AG in 1997. He had an active role in the spinoff and formation of Aeterna Zentaris GmbH from ASTA Medica. Dr. Paulini has managed many of the Company’s clinical development projects including research and development of Macrilen (macimorelin). Dr. Paulini obtained his PhD (Dr. Ing.) in chemistry at the Technical University Darmstadt (Germany) in 1993 and specialized in medicinal chemistry and drug discovery during subsequent postdoctoral fellowships at Strathclyde University (Glasgow, Scotland) and J.W. Goethe University (Frankfurt, Germany).

The board of directors of the Company thanks Mr. Ward for his contribution to the Company and wishes him all the best in the future